# Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery

> **NCT06887621** · PHASE2 · RECRUITING · sponsor: **Instituto do Cancer do Estado de São Paulo** · enrollment: 276 (estimated)

## Conditions studied

- Post Operative Nausea and Vomiting (PONV)

## Interventions

- **DRUG:** Encapsulated amisulpride 50 mg (matched for color, weight, smell and size)
- **DRUG:** Encapsulated placebo (matched for color, weight, smell and size)

## Key facts

- **NCT ID:** NCT06887621
- **Lead sponsor:** Instituto do Cancer do Estado de São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-10
- **Primary completion:** 2027-03-29
- **Final completion:** 2027-03-31
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2025-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06887621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06887621, "Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06887621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*